Pfizer Inc. shares rose on the back of positive financial results: in the second quarter, the company’s revenue increased by 10% year over year to $14.7 billion, while adjusted earnings per share came in at $0.78, up 30% from the previous year.

Investors were also attracted by a high dividend yield of about 6.9%. Over the past five years, Pfizer has raised dividends five times, maintaining a payout ratio of 51% of earnings. Although cash flow in the first half of the year amounted to only $571 million compared to dividend payments of $4.9 billion, management assured improvement in the second half thanks to the Seagen integration and the launch of new drugs.

On the technical chart, a “golden cross” formed in August — the 50-day moving average crossed above the 200-day moving average, signaling a potential upward trend.

Key growth drivers remain Paxlovid, Comirnaty, Abrysvo, as well as oncology drugs Xtandi and Padcev. However, the company faces challenges from the loss of exclusivity of major medicines and increased competition from Novartis and Eli Lilly.

Analysts note that Pfizer shares remain attractive for long-term investors thanks to the combination of high yield, new products, and improved cash flow.